Seventh Sense Biosystems Raises $16M in Series B Financing

Seventh_SenseSeventh Sense Biosystems, Inc., a Cambridge, MA-based developer of virtually painless blood collection and diagnostic platforms, raised $16m in Series B financing.

Backers included new investors the Venture Capital unit of Siemens Financial Services (SFS VC), Novartis and Laboratory Corporation of America® Holdings (LabCorp®) and existing investors Flagship Ventures and Polaris Partners.

The company intends to use the funds to complete the development of its platform.

Founded in 2008, within Flagship VentureLabs™ and led by Howard Weisman, Chief Executive Officer, 7SBio is developing and commercializing an array of products based on its proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform, with an initial focus on enabling diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection.



Join the discussion